Study compares effectiveness of psoriasis treatments

April 20, 2012
Study compares effectiveness of psoriasis treatments
The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Joel M. Gelfand, M.D., M.S.C.E., of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues compared the effectiveness of biologic systemic therapy, nonbiologic , and phototherapy for treatment of psoriasis in a cohort of 713 patients with plaque psoriasis. Participants received monotherapy (methotrexate sodium, , , or ustekinumab) or narrowband ultraviolet (UV)-B phototherapy. The primary outcome was clear or almost clear skin on the Physician Global Assessment Scale.

The researchers found that the proportion of patients who achieved the primary outcome was 23.8 percent with methotrexate, 47.7 percent with adalimumab, 34.2 percent with etanercept, 36.1 percent with ustekinumab, and 26.1 percent with narrowband UV-B. Patients receiving adalimumab, etanercept, and ustekinumab were significantly more likely to achieve the primary outcome than those receiving methotrexate, whereas there was no significant difference for those receiving phototherapy versus methotrexate. There was no response difference seen for quality of life.

"The effectiveness of psoriasis therapies in clinical practice may be lower than that reported in previous trials," the authors write. "These results provide novel benchmarks emphasizing the critical importance of studying effectiveness in real-world practice."

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Arch Dermatol. 2012;148(4):487-494. doi:10.1001/archdermatol.2012.370

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Recommended for you

Resveratrol may be an effective intervention for lung aging

February 22, 2017

In a study led by Barbara Driscoll, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, researchers demonstrate, for the first time that inhaled resveratrol treatments slow aging-related degenerative ...

Salmonella food poisoning could damage your DNA

February 22, 2017

Salmonella food poisoning wallops you for several days, but new research by Cornell food scientists indicates that some of its serotypes – variations of the bacterial species – can have permanent repercussions. It may ...

Risk of Ross River virus global epidemic

February 22, 2017

Australia's Ross River virus (RRV) could be the next mosquito-borne global epidemic according to a new research study led by the University of Adelaide and The Australian National University.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.